|
|
|
|
BusinessWeek
--
AstraZeneca's Iressa took an FDA hit in 2005 as a lung cancer treatment, but a recent study showed its potential in breast cancer patients
There may be a second life for Iressa, AstraZeneca's once-promising cancer drug that came to symbolize the hype s..
Read More
|
|
|
BusinessWeek
--
Billions of dollars are spent developing cancer drugs, but precious few get approved. Is the FDA part of the problem?
Editor's note: For a CBS Evening News report on the challenges confronting new cancer drug approvals, which was made in collaboration..
Read More
|
|
|
BusinessWeek
--
The FDA approval of the breast cancer treatment, which was opposed by advisory panels, shocked patients, doctors, and investors
When the Food & Drug Administration announced late on Feb. 22 that it had swept aside the objections of its expert advisers..
Read More
|
|
|
CNN
--
Clinical immunologist Dr. Ian Frazer is experiencing what many scientists can only dream of; developing a vaccine in a laboratory and then seeing it being used and marketed all over the world.
The 2006 Australian of the Year spent 20 years researching..
Read More
|
|
|
BusinessWeek
--
Shares fell Friday after the biotech announced unsuccessful clinical trial results for cancer drugs
Amgen (AMGN) has been fighting to prove that its colon cancer drug Vectibix can help save patients who are using a chemotherapy treatment in combination..
Read More
|
|
